Single-dose rituximab for recurrent glomerulonephritis post-renal transplant.

CONCLUSION: Single-dose rituximab for treatment of recurrent GN was associated with less subsequent rejection and longer time to graft loss without increased infection, but was no more effective than regimens not using rituximab at 36-months except those with recurrent membranous GN. © 2015 S. Karger AG, Basel. PMID: 25634230 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25634230?dopt=Abstract

Source: American Journal of Nephrology - February 5, 2015 Category: Urology & Nephrology Authors: Spinner ML, Bowman LJ, Horwedel TA, Delos Santos RB, Klein CL, Brennan DC Tags: Am J Nephrol Source Type: research